• Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529)
• Validates RECCE® anti-infectives for treating bacterial infections, viral infections, and more
• Administration by oral, inhalation, transdermal, or injection

Recce Pharmaceuticals Limited has announced the receipt of a Notice of Acceptance from the China National Intellectual Property Administration for Patent Family 4 for its RECCE® Anti-infectives, with an expiry date of 2041. The China Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), covering the process for preparation, use for the treatment of disease (particularly bacterial and viral infections), and administration methods including oral, inhalation, transdermal, and injection. This is the company's fifth Family 4 patent, alongside existing patents in Australia, Canada, Israel, and Japan, with further Patent Cooperation Treaty Country (PCT) submissions in respective stages of review, allowance, or grant. China is the world's second-largest pharmaceutical market, with the Chinese antibiotic market valued at approximately US$4.09 billion and projected to grow at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2030. Recce Pharmaceuticals' Chief Executive Officer, James Graham, stated that this patent will broaden the company's patent portfolio for Family 4 in the second-largest pharmaceutical market, and that the China National Intellectual Property Administration's recognition of the technical advantages of Recce's new class of anti-infectives is appreciated.